Mycoplasma hyopneumoniae type I signal peptidase: expression and evaluation of its diagnostic potential

Lucas Moitinho-Silva1, Bianca L Heineck, Luciano A Reolon

  • 1Laboratório de Genômica Estrutural e Funcional, Centro de Biotecnologia, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

Veterinary Microbiology
|August 12, 2011
PubMed

Insights

Type I signal peptidase (SPase I) from Mycoplasma hyopneumoniae is expressed in different strains and shows potential as an antigen for diagnosing porcine enzootic pneumonia (PEP). This protein could also be a target for new antibiotics.

Area of Science:

  • Microbiology
  • Molecular Biology
  • Immunology

Background:

  • Mycoplasma hyopneumoniae causes porcine enzootic pneumonia (PEP).
  • Type I signal peptidase (SPase I), encoded by sipS, is crucial for the general secretory pathway in bacteria.
  • Understanding SPase I expression and antigenicity is key for diagnostics and therapeutics.

Purpose of the Study:

  • To analyze the expression of M. hyopneumoniae SPase I (MhSPase I) in different strains.
  • To evaluate the potential of recombinant MhSPase I (rMhSPase I) as an immunodiagnostic antigen for PEP.
  • To explore MhSPase I as a potential target for antibiotic development.

Main Methods:

  • Quantitative reverse transcriptase PCR (qRT-PCR) to analyze sipS gene expression.
  • Immunoblot assays to detect MhSPase I protein levels.
  • Expression of recombinant rMhSPase I in Escherichia coli.
  • Immunization of mice with rMhSPase I and antibody characterization.
  • Phylogenetic analysis of MhSPase I.

Main Results:

  • The sipS gene is likely part of an operon, co-transcribed with other genes.
  • MhSPase I is expressed at the protein level in all analyzed M. hyopneumoniae strains, with higher levels in a pathogenic strain.
  • Recombinant MhSPase I is immunogenic and specific, showing no cross-reactivity with other Mycoplasma species.
  • Phylogenetic analysis reveals low conservation with related bacterial proteins.
  • An ELISA based on rMhSPase I shows potential for PEP immunodiagnosis.

Conclusions:

  • MhSPase I is expressed in M. hyopneumoniae, with variations in protein levels between strains.
  • rMhSPase I is a promising antigen for serodiagnosis of PEP.
  • MhSPase I is a potential candidate for vaccine development and a target for novel antibiotics.